• Explore /
  • Poster
  • / Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).

Abstract Poster

Authors

null

Laura Graham

University of Washington, Seattle, WA

Laura Graham , Nicholas Reder , Roman Gulati , Petros Grivas , Jonathan L. Wright , Evan Y. Yu , Wendy Hou , Katie Nega , Todd Yezefski , Robert B. Montgomery , Elahe A. Mostaghel , William J. Ellis , Lawrence D. True , Daniel W. Lin , Peter Nelson , Michael Thomas Schweizer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT02849990

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5081)

DOI

10.1200/JCO.2019.37.15_suppl.5081

Abstract #

5081

Poster Bd #

193

Abstract Disclosures

Similar Posters

First Author: Rahul Raj Aggarwal

First Author: Junlong Zhuang

First Author: Junlong Zhuang

First Author: Rana R. McKay